Frederik van Delft Consultant Oncologist Newcastle

Frederik van Delft Consultant Oncologist Newcastle: Expert in Adolescent Haematological Oncology

Frederik van Delft Consultant Oncologist Newcastle leads cutting-edge research and clinical care for adolescents and young adults with blood cancers. As both a clinician and scientist, Dr Van Delft provides compassionate care while driving innovation in the field of paediatric and young adult oncology.

Career and Academic Background

Dr Frederik van Delft began his medical journey at the Katholieke Universiteit Leuven in Belgium. He then pursued postgraduate training in paediatrics and paediatric haematology/oncology at the Vrije Universiteit Brussel and Great Ormond Street Hospital in London. Throughout this time, he developed a strong passion for improving cancer outcomes in children and young people.

Later, he completed a PhD in leukaemia molecular genetics at Barts and the London Medical School, Queen Mary University of London. This research laid the foundation for his future scientific contributions.

Clinical Roles in Newcastle and Beyond

As an honorary consultant in adolescent oncology, Dr Van Delft currently divides his time between the Great North Children’s Hospital and Newcastle University. His clinical role focuses on enhancing the treatment and overall experience of teenagers and young adults diagnosed with leukaemia or lymphoma.

He also contributes actively at the Newcastle University Cancer Centre. His research there aims to uncover resistance mechanisms in T-cell malignancies and design new strategies to counteract them. These findings could significantly improve treatment effectiveness and long-term survival.

Frederik van Delft Consultant Oncologist Newcastle: Research Focus and Impact

Dr Van Delft’s team works to understand and combat complications such as venous thromboembolism (VTE) and neurotoxicity, which can occur during cancer treatment. By identifying underlying mechanisms, he hopes to prevent or better manage these side effects.

His research group has also developed the infrastructure to study drug resistance in paediatric cancers. With each discovery, the goal remains the same: to save lives and improve quality of care.

Memberships, Trials, and Collaborations

Dr Van Delft contributes to numerous national and international clinical research groups. He is a member of:

• The CCLG and NCRI Teenage and Young Adult Clinical Study Group (TYA CSG) Biological Studies Subgroup

• The Resistant Disease Committee of the International Berlin-Frankfurt-Munster / SIOPe Childhood Leukaemia Study Group

• He also acts as the local Principal Investigator for the EuroNet Paediatric Hodgkin Lymphoma trials

Through collaboration, he helps design future trials for patients with relapsed T-cell acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL).

Passion for Young Cancer Patients

Dr Van Delft’s special interest lies in teenage and young adult haematological oncology. Every step of his career reflects a commitment to bridging research with patient care. By combining clinical experience with scientific discovery, he works tirelessly to shape a better future for young people with cancer.